Gene: FLT3 ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913487
rs121913487
FLT3
T 0.800 CausalMutation CLINVAR FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. 15374878

2005
dbSNP: rs121913487
rs121913487
FLT3
C 0.800 CausalMutation CLINVAR Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. 15256420

2004
dbSNP: rs121913487
rs121913487
FLT3
T 0.800 CausalMutation CLINVAR Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. 15256420

2004
dbSNP: rs121913487
rs121913487
FLT3
T 0.800 CausalMutation CLINVAR Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. 11290608

2001
dbSNP: rs121913487
rs121913487
FLT3
C 0.800 CausalMutation CLINVAR Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. 11290608

2001
dbSNP: rs121913487
rs121913487
FLT3
0.800 GeneticVariation UNIPROT

dbSNP: rs121913488
rs121913488
FLT3
0.740 GeneticVariation BEFREE The FLT3 receptor tyrosine kinase plays an integral role in hematopoiesis, and one third of AML diagnoses exhibit gain-of-function mutations in FLT3, with the juxtamembrane domain internal tandem duplication (ITD) and the kinase domain D835Y variants observed most frequently. 30541869

2019
dbSNP: rs121913488
rs121913488
FLT3
0.740 GeneticVariation BEFREE Retroviral expression of FLT3-N676K in myeloid 32D cells induced AML in syngeneic C3H/HeJ mice (n = 11/13, median latency 58 days), with a transforming activity similar to FLT3-internal tandem duplication (ITD) (n = 8/8), FLT3-TKD D835Y (n = 8/9), and FLT3-ITD-N676K (n = 9/9) mutations. 26891877

2016
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 23783394

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs121913488
rs121913488
FLT3
T 0.740 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013
dbSNP: rs121913488
rs121913488
FLT3
T 0.740 CausalMutation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. 23321257

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations. 24046014

2013
dbSNP: rs121913488
rs121913488
FLT3
0.740 GeneticVariation BEFREE In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations. 24046014

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. 23714533

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. 23714533

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 23783394

2013
dbSNP: rs121913488
rs121913488
FLT3
T 0.740 CausalMutation CLINVAR The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 23783394

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. 23321257

2013
dbSNP: rs121913488
rs121913488
FLT3
A 0.740 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013
dbSNP: rs121913488
rs121913488
FLT3
G 0.740 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013